Mylan invests $20m more in Mapi's monthly Copaxone
-
Mylan invests $20m more in Mapi's monthly Copaxone
https://en.globes.co.il/en/article-mylan-invests-20m-more-in-mapis-monthly-copaxone-1001332440
Mapi Pharma hopes to manufacture delayed release Copaxone that can be taken twice a month, instead of twice a week with the current version.Saa maa det sidste soem efterhaanden vaere slaaet i den kiste
-
MrG Den udgoer mindre end 1% af min portefoelje, saa jeg ved ikke, om jeg kan tillade mig at sige, at jeg er med ombord. Ajovy
uden auto-injektor har vaeret en skuffelse, men ellers gaar det helt efter planen. Jeg har ingen grund til at tro, at de ikke naar i maal inden 2023. -
Emgality
Demonstrates Reduction in Frequency, Duration, and Pain Severity in Patients with Episodic and Chronic Migraine
https://investor.lilly.com/news-releases/news-release-details/emgalityr-demonstrates-reduction-frequency-duration-and-pain
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind